Stocks Buzz: Eli Lilly and Company (LLY), Synchrony Financial (SYF), Enterprise Products Partners L.P. (EPD)

Eli Lilly and Company (LLY) failed to extend gains with the stock declining -0.26% or $-0.21 to close the day at $80.04 on light trading volume of 3.63M shares, compared to its three month average trading volume of 6.13M. The Indianapolis Indiana 46285 based company has been outperforming the drug manufacturers – major group over the past 52 weeks, with the stock gaining 11.84%, compared to the industry which has advanced 13.14% over the same period. With RSI of 72.6, the stock should still continue to rise and get closer to its one year target estimate of $86.35, making it a hold for now.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Synchrony Financial (SYF) retreated with the stock falling -1.15% or $-0.43 to close at $36.85 on light trading volume of 3.62M compared its three months average trading volume of 6.13M. The Stamford Connecticut 06902 based company operating under the Credit Services industry has been trending up for the last 52 weeks, with the shares price now 40.22% up for the period and up by 1.97% so far this year. With price target of $42.91 and a 60.55% rebound from 52-week low, Synchrony Financial has plenty of upside potential, making it a hold with a view buy.

Synchrony Financial operates as a consumer financial services company in the United States. The company offers private label credit cards, dual cards, and small and medium-sized business credit products; and promotional financing for consumer purchases, such as private label credit cards and installment loans. It also provides promotional financing to consumers for elective healthcare procedures or services, such as dental, veterinary, cosmetic, vision, and audiology; debt cancellation products; and deposit products, including certificates of deposit, individual retirement, money market, and savings accounts, as well as accepts deposits through third-party securities brokerage firms. The company offers its credit products through programs established with a group of national and regional retailers, local merchants, manufacturers, buying groups, industry associations, and healthcare service providers; and deposit products through multiple channels, including online, print, and radio advertising. Synchrony Financial was incorporated in 2003 and is headquartered in Stamford, Connecticut. Synchrony Financial operates independently of GE Consumer Finance, Inc. as of November 17, 2015.

Enterprise Products Partners L.P. (EPD) failed to extend gains with the stock declining -0.24% or $-0.07 to close the day at $28.87 on lower than average trading volume of 3.6M shares, compared to its three month average trading volume of 5.2M. The Houston Texas 77002 based company has been outperforming the independent oil & gas companies by 12.7969% for last three months and its recent gains have pushed the stock slightly up 6.77% YTD, versus the independent oil & gas industry which is down -3.29% for the same period. The RSI of 62.23 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Enterprise Products Partners L.P., a master limited partnership, provides midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals, and refined products. The company operates through NGL Pipelines & Services, Crude Oil Pipelines & Services, Natural Gas Pipelines & Services, and Petrochemical & Refined Products Services segments. The NGL Pipelines & Services segment provides natural gas processing and related NGL marketing services, as well as NGL export docks and related services. It operates approximately 19,500 miles of NGL pipelines; NGL and related product storage facilities; 15 NGL fractionators; and a liquefied petroleum gas export terminal and NGL import facility. The Crude Oil Pipelines & Services segment operates approximately 5,400 miles of crude oil pipelines and related operations; and crude oil storage and marine terminals located in Oklahoma and Texas, as well as a fleet of 478 tractor-trailer tank trucks used to transport crude oil. It also engages in crude oil marketing activities. The Natural Gas Pipelines & Services segment operates approximately 19,100 miles of natural gas pipeline systems to gather and transport natural gas in Colorado, Louisiana, New Mexico, Texas, and Wyoming. It leases underground salt dome natural gas storage facilities in Texas and Louisiana; owns an underground salt dome storage cavern in Texas; and markets natural gas. The Petrochemical & Refined Products Services segment operates propylene fractionation and related operations, including 674 miles of pipelines; butane isomerization complex, associated deisobutanizer units, and related pipeline assets; and octane enhancement and high purity isobutylene production facilities. It also operates refined products pipelines of approximately 4,200 miles; and terminals, as well as provides refined products marketing and marine transportation services. The company was founded in 1968 and is based in Houston, Texas.

 

Stocks Under Consideration: DENTSPLY SIRONA Inc. (XRAY), Eli Lilly and Company (LLY), Microsoft Corporation (MSFT)

DENTSPLY SIRONA Inc. (XRAY) grew with the stock adding 1.53% or $0.9 to close at $59.74 on active trading volume of 2.23M compared its three months average trading volume of 1.57M. The York Pennsylvania 17405 based company operating under the Medical Instruments & Supplies industry has been trending up for the last 52 weeks, with the shares price now 7.81% up for the period and up by 3.48% so far this year. With price target of $66.5 and a 11.1% rebound from 52-week low, DENTSPLY SIRONA Inc. has plenty of upside potential, making it a hold with a view buy.

DENTSPLY International Inc. designs, develops, manufactures, and markets various consumable dental products for the professional dental market in the United States and internationally. The company provides dental consumable products, including dental anesthetics, prophylaxis paste, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride; and small equipment products comprising dental handpieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. It also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials, as well as computer aided design and machining ceramic systems, and porcelain furnaces. In addition, the company provides dental specialty products, which include endodontic instruments and materials, implants and related products, 3D digital scanning and treatment planning software, and dental and orthodontic appliances and accessories. Further, it offers consumable medical device products, such as urology catheters, various surgical products, medical drills, and other products. The company markets and sells its dental products through distributors, dealers, and importers to dentists, dental hygienists, dental assistants, dental laboratories, and dental schools; and medical products directly, as well as through distributors to urologists, urology nurses, and general practitioners. DENTSPLY International Inc. was founded in 1899 and is headquartered in York, Pennsylvania.

Eli Lilly and Company (LLY) had a light trading with around 3.31M shares changing hands compared to its three month average trading volume of 6.11M. The stock traded between $77.25 and $78.83 before closing at the price of $78.81 with 1.34% change on the day. The Indianapolis Indiana 46285 based company is currently trading 23.62% above its 52 week low of $64.18 and -4.08% below its 52 week high of $83.79. Both the RSI indicator and target price of  and $86.35 respectively, lead us to believe that it could rise over the coming weeks.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Microsoft Corporation (MSFT) saw its value decrease by -0.23% as the stock dropped $-0.15 to finish the day at a closing price of $64.57. The stock was lighter in trading and has fluctuated between $48.04-$65.91 per share for the past year. The shares, which traded within a range of $64.02 to $64.72 during the day, are up by 10.14% in the past three months and up by 12.55% over the past six months. It is currently trading 1.39% above its 20 day moving average and 2.75% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $68.97 a share over the next twelve months. The current relative strength index (RSI) reading is 59.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Microsoft Corporation, a technology company, develops, licenses, and supports software products, services, and devices worldwide. The company’s Productivity and Business Processes segment offers Office 365 commercial products and services for businesses, including Office, Exchange, SharePoint, and Skype, as well as related Client Access Licenses (CALs); Office 365 consumer services, such as Skype, Outlook.com, and OneDrive; Dynamics business solutions, such as financial management, customer relationship management, supply chain management, and analytics applications for small and mid-size businesses, large organizations, and divisions of enterprises; and LinkedIn online professional network. Its Intelligent Cloud segment licenses server products and cloud services, such as SQL Server, Windows Server, Visual Studio, System Center, and related CALs, as well as Azure, a cloud platform with computing, networking, storage, database, and management services; and enterprise services, such as Premier Support and Microsoft Consulting that assist in developing, deploying, and managing Microsoft server and desktop solutions, as well as provide training and certification to developers and IT professionals on Microsoft products. The company’s More Personal Computing segment comprises Windows OEM, volume, and other non-volume licensing of the Windows operating system, as well as patent licensing, Windows Embedded, MSN display advertising, and Windows Phone licensing system; devices, including Microsoft Surface, phones, and PC accessories; and search advertising, including Bing and Bing Ads. This segment also provides gaming platforms, including Xbox hardware, Xbox Live, video games, and third-party video games. The company markets and distributes its products through original equipment manufacturers (OEM), distributors, and resellers, as well as through online and Microsoft retail stores. Microsoft Corporation was founded in 1975 and is headquartered in Redmond, Washington.

 

Worth Watching Stocks: Dollar General Corporation (DG), Eli Lilly and Company (LLY), TD Ameritrade Holding Corporation (AMTD)

Dollar General Corporation (DG) saw its value decrease by -1.18% as the stock dropped $-0.92 to finish the day at a closing price of $76.79. The stock was lighter in trading and has fluctuated between $66.5-$96.88 per share for the past year. The shares, which traded within a range of $76.24 to $78.02 during the day, are up by 7.75% in the past three months and down by -16.62% over the past six months. It is currently trading 5.53% above its 20 day moving average and 3.31% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $79.98 a share over the next twelve months. The current relative strength index (RSI) reading is 61.28.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Dollar General Corporation, a discount retailer, provides various merchandise products in the southern, southwestern, midwestern, and eastern United States. The company offers consumable products, including paper and cleaning products comprising paper towels, bath tissues, paper dinnerware, trash and storage bags, and laundry and other home cleaning supplies; packaged food products, such as cereals, canned soups and vegetables, condiments, spices, sugar, and flour; perishables consisting of milk, eggs, bread, frozen meals, beer, and wine; snacks that comprise candies, cookies, crackers, salty snacks, and carbonated beverages; health and beauty products, such as over-the-counter medicines, as well as soap, body wash, shampoo, dental hygiene, and foot care products; pet products, which include pet supplies and pet food; and tobacco products. It also provides seasonal products, including decorations, toys, batteries, small electronics, greeting cards, stationery products, prepaid phones and accessories, gardening supplies, hardware products, and automotive and home office supplies; and home products consisting of kitchen supplies, cookware, small appliances, light bulbs, storage containers, frames, candles, craft supplies and kitchen products, beds, and bath soft goods. In addition, the company offers apparel for infants, toddlers, girls, boys, women, and men, as well as socks, underwear, disposable diapers, shoes, and accessories. As of October 28, 2016, it operated 13,205 stores located in 43 states. The company was formerly known as J.L. Turner & Son, Inc. and changed its name to Dollar General Corporation in 1968. Dollar General Corporation was founded in 1939 and is based in Goodlettsville, Tennessee.

Eli Lilly and Company (LLY) shares were up in last trading by 0.12% to $77.79. It experienced lighter than average volume on day. The stock increased in value by almost 0.73% over the past week and grew 3.36% in the past month. It is currently trading 5.77% above its 50 day moving average and 2.19% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -5.96% decrease in value from its one year high of $83.79. The RSI indicator value of 64.64, lead us to believe that it is a hold for now.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

TD Ameritrade Holding Corporation (AMTD) traded within a range of $42.33 to $42.95 after opening the day at $42.95. The company has seen its stock decrease in value by -2.52% so far this year. The stock was down close to -0.63% on light volume in last trading session and closed at $42.34 per share. After the recent fall, the stock is currently holding -10.35% below its 52 week high of $47.41 and 73.69% above its 12-month low of $26.37. The shares are up by over 20.41% in the last three months, and the RSI indicator value of 36.52 is neither bullish nor bearish, tempting investors to stay on the sidelines.

TD Ameritrade Holding Corporation provides securities brokerage services and related technology-based financial services to retail investors, traders, and independent registered investment advisors (RIAs) in the United States. Its products and services include tdameritrade.com, a Web platform for self-directed retail investors; Trade Architect, a Web-based platform for investors and traders to identify opportunities and stay informed; thinkorswim, a desktop platform for traders; and TD Ameritrade Mobile, which allows on-the-go investors and traders to trade and monitor accounts. The company also offers TD Ameritrade Institutional that provides brokerage and custody services to approximately 5,000 independent RIAs and their clients; TD Ameritrade’s Goal Planning, which offers investment consulting and planning services; Investools, a suite of investor education products and services for stock, option, foreign exchange, futures, mutual fund, and fixed-income investors; Amerivest, an advisory service that develops portfolios of exchange-traded funds (ETFs) and mutual funds; AdvisorDirect, a national referral service for investors; and TD Ameritrade Corporate Services that provide self-directed brokerage services to employees of corporations. In addition, it offers various retail brokerage products and services, such as common and preferred stocks; ETFs; options; futures; foreign exchange; mutual funds; fixed income products; primary and secondary offerings of fixed income securities, closed-end funds, and preferred stocks; margin lending; cash management services; and annuities. The company provides its services primarily through the Internet, a network of retail branches, mobile trading applications, interactive voice response, and registered representatives through telephone. TD Ameritrade Holding Corporation was founded in 1971 and is headquartered in Omaha, Nebraska.

 

Worth Watching Stocks: McDonald’s Corporation (MCD), Enterprise Products Partners L.P. (EPD), Eli Lilly and Company (LLY)

McDonald’s Corporation (MCD) saw its value increase by 0.06% as the stock gained $0.08 to finish the day at a closing price of $124.67. The stock was lighter in trading and has fluctuated between $110.33-$131.96 per share for the past year. The shares, which traded within a range of $124.49 to $125.36 during the day, are up by 11.36% in the past three months and up by 7.02% over the past six months. It is currently trading 1.85% above its 20 day moving average and 2.44% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $131.17 a share over the next twelve months. The current relative strength index (RSI) reading is 67.91.The technical indicator lead us to believe there will be no major movement any time soon, hold.

McDonald’s Corporation operates and franchises McDonald’s restaurants in the United States, Europe, the Asia/Pacific, the Middle East, Africa, Canada, and Latin America. The company’s restaurants offer various food products, soft drinks, coffee, and other beverages. As of December 31, 2015, it operated 36,525 restaurants, including 30,081 franchised restaurants comprising 21,147 franchised to conventional franchisees, 5,529 licensed to developmental licensees, and 3,405 licensed to foreign affiliates; and 6,444 company-operated restaurants. The company has strategic partnerships with CITIC Limited, CITIC Capital, and The Carlyle Group to expand its business in Mainland China and Hong Kong. McDonald’s Corporation was founded in 1940 and is based in Oak Brook, Illinois.

Enterprise Products Partners L.P. (EPD) shares were up in last trading by 0.11% to $28.43. It experienced lighter than average volume on day. The stock increased in value by almost 1.07% over the past week and grew 3.16% in the past month. It is currently trading 5.22% above its 50 day moving average and 4.76% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -6.02% decrease in value from its one year high of $30.25. The RSI indicator value of 56.9, lead us to believe that it is a hold for now.

Enterprise Products Partners L.P., a master limited partnership, provides midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals, and refined products. The company operates through NGL Pipelines & Services, Crude Oil Pipelines & Services, Natural Gas Pipelines & Services, and Petrochemical & Refined Products Services segments. The NGL Pipelines & Services segment provides natural gas processing and related NGL marketing services, as well as NGL export docks and related services. It operates approximately 19,500 miles of NGL pipelines; NGL and related product storage facilities; 15 NGL fractionators; and a liquefied petroleum gas export terminal and NGL import facility. The Crude Oil Pipelines & Services segment operates approximately 5,400 miles of crude oil pipelines and related operations; and crude oil storage and marine terminals located in Oklahoma and Texas, as well as a fleet of 478 tractor-trailer tank trucks used to transport crude oil. It also engages in crude oil marketing activities. The Natural Gas Pipelines & Services segment operates approximately 19,100 miles of natural gas pipeline systems to gather and transport natural gas in Colorado, Louisiana, New Mexico, Texas, and Wyoming. It leases underground salt dome natural gas storage facilities in Texas and Louisiana; owns an underground salt dome storage cavern in Texas; and markets natural gas. The Petrochemical & Refined Products Services segment operates propylene fractionation and related operations, including 674 miles of pipelines; butane isomerization complex, associated deisobutanizer units, and related pipeline assets; and octane enhancement and high purity isobutylene production facilities. It also operates refined products pipelines of approximately 4,200 miles; and terminals, as well as provides refined products marketing and marine transportation services. The company was founded in 1968 and is based in Houston, Texas.

Eli Lilly and Company (LLY) traded within a range of $77.19 to $78.65 after opening the day at $77.44. The company has seen its stock increase in value by 6.2% so far this year. The stock was up close to 0.53% on light volume in last trading session and closed at $78.11 per share. After the recent gain, the stock is currently holding -5.57% below its 52 week high of $83.79 and 21.7% above its 12-month low of $64.18. The shares are up by over 6.42% in the last three months, and the RSI indicator value of 67.31 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

 

Stocks To Track: HCA Holdings, Inc. (HCA), Eli Lilly and Company (LLY), Noble Energy, Inc. (NBL)

HCA Holdings, Inc. (HCA) fell -1.35% during last trading as the stock lost $-1.13 to finish the day at $82.67 with about 2.81M shares changing hands, compared to its three month average trading volume of 3.14M. The $30.42B market cap company, which fluctuated between $82.59 and $84.26 during the day, currently situated 29.43% above its 52 week low of $63.87 and -1.72% away from its one year high of $84.26. The RSI of 67.77 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

HCA Holdings, Inc., through its subsidiaries, provides health care services in the United States. It operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services. The company also operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adult and adolescent alcohol and drug abuse treatment, and counseling. In addition, it operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. As of December 31, 2015, the company operated 164 general, acute care hospitals with 43,275 licensed beds; 3 psychiatric hospitals with 396 licensed beds; and 1 rehabilitation hospital, as well as 116 freestanding surgery centers. HCA Holdings, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Eli Lilly and Company (LLY) gained $0.6 to close the day at a new closing price of $77.83, a 0.78% increase in value from its previous closing price that moved the stock 21.27% above its 52 week low of $64.18. A total of 2.81M shares exchanged hands during the day compared with its three month average trading volume of 6.25M. The stock, which fluctuated between $76.76 and $77.85 during the day, currently situated -5.91% below its 52 week high. The stock is up by 2.96% in the past one month and up by 8.64% over the past three months. With a one year target estimate of $86.3 and RSI of 65.68, the stock still has upside potential, making it a hold for now.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Noble Energy, Inc. (NBL) had a light trading with around 2.76M shares changing hands compared to its three month average trading volume of 4.26M. The stock traded between $39.61 and $40.52 before closing at the price of $39.86 with -1.09% change on the day. The Houston Texas 77070 based company is currently trading 50.88% above its 52 week low of $26.71 and -4.92% below its 52 week high of $42.03. Both the RSI indicator and target price of 54.15 and $46.91 respectively, lead us to believe that it should be put on hold over the coming weeks.

Noble Energy, Inc., an independent energy company, engages in the acquisition, exploration, and production of crude oil, natural gas, and natural gas liquids worldwide. Its principal projects are located in DJ Basin, Marcellus Shale, Eagle Ford Shale, and Permian Basin, the United States; deepwater Gulf of Mexico; offshore Eastern Mediterranean; and offshore West Africa. As of December 31, 2015, the company had approximately 1,421 million barrels oil equivalent of total proved reserves. Noble Energy, Inc. was founded in 1932 and is headquartered in Houston, Texas.

 

Trader Alert: Enterprise Products Partners L.P. (EPD), AmerisourceBergen Corporation (ABC), Eli Lilly and Company (LLY)

Enterprise Products Partners L.P. (EPD) grew with the stock adding 0.11% or $0.03 to close at $28.16 on light trading volume of 3.84M compared its three months average trading volume of 5.23M. The Houston Texas 77002 based company operating under the Independent Oil & Gas industry has been trending up for the last 52 weeks, with the shares price now 20.24% up for the period and up by 4.14% so far this year. With price target of $32.04 and a 43.38% rebound from 52-week low, Enterprise Products Partners L.P. has plenty of upside potential, making it a hold with a view buy.

Enterprise Products Partners L.P., a master limited partnership, provides midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals, and refined products. The company operates through NGL Pipelines & Services, Crude Oil Pipelines & Services, Natural Gas Pipelines & Services, and Petrochemical & Refined Products Services segments. The NGL Pipelines & Services segment provides natural gas processing and related NGL marketing services, as well as NGL export docks and related services. It operates approximately 19,500 miles of NGL pipelines; NGL and related product storage facilities; 15 NGL fractionators; and a liquefied petroleum gas export terminal and NGL import facility. The Crude Oil Pipelines & Services segment operates approximately 5,400 miles of crude oil pipelines and related operations; and crude oil storage and marine terminals located in Oklahoma and Texas, as well as a fleet of 478 tractor-trailer tank trucks used to transport crude oil. It also engages in crude oil marketing activities. The Natural Gas Pipelines & Services segment operates approximately 19,100 miles of natural gas pipeline systems to gather and transport natural gas in Colorado, Louisiana, New Mexico, Texas, and Wyoming. It leases underground salt dome natural gas storage facilities in Texas and Louisiana; owns an underground salt dome storage cavern in Texas; and markets natural gas. The Petrochemical & Refined Products Services segment operates propylene fractionation and related operations, including 674 miles of pipelines; butane isomerization complex, associated deisobutanizer units, and related pipeline assets; and octane enhancement and high purity isobutylene production facilities. It also operates refined products pipelines of approximately 4,200 miles; and terminals, as well as provides refined products marketing and marine transportation services. The company was founded in 1968 and is based in Houston, Texas.

AmerisourceBergen Corporation (ABC) dropped $-0.56 to close the day at a new closing price of $88.05, a -0.63% decrease in value from its previous closing price that moved the stock 29.36% above its 52 week low of $68.38. A total of 3.84M shares exchanged hands during the day compared with its three month average trading volume of 2.78M. The stock, which fluctuated between $86.57 and $88.78 during the day, currently situated -3.54% below its 52 week high. The stock is up by 6.59% in the past one month and up by 26.75% over the past three months. With a one year target estimate of $87.63 and RSI of 61.77, the stock still has upside potential, making it a hold for now.

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment provides pharmaceutical distribution and other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers. The company’s Other segment provides commercialization support services, including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers; specialty transportation and logistics services for the biopharmaceutical industry; and animal health care products. It markets its products and services through independent sales forces and marketing organizations. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.

Eli Lilly and Company (LLY) shares were down in last trading by -0.27% to $77.39. It experienced lighter than average volume on day. The stock increased in value by almost 3.77% over the past week and grew 3.74% in the past month. It is currently trading 6.16% above its 50 day moving average and 1.74% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -6.44% decrease in value from its one year high of $83.79. The RSI indicator value of 63.9, lead us to believe that it is a hold for now.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

 

3 Stocks to Watch For: Eli Lilly and Company (LLY), PayPal Holdings, Inc. (PYPL), Agilent Technologies, Inc. (A)

Eli Lilly and Company (LLY) saw its value increase by 3.12% as the stock gained $2.33 to finish the day at a closing price of $77.03. The stock was higher in trading and has fluctuated between $64.18-$83.79 per share for the past year. The shares, which traded within a range of $74 to $77.28 during the day, are up by 4.03% in the past three months and down by -6.19% over the past six months. It is currently trading 1.68% above its 20 day moving average and 5.66% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $85.76 a share over the next twelve months. The current relative strength index (RSI) reading is 62.85.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

PayPal Holdings, Inc. (PYPL) shares were down in last trading by -0.2% to $39.78. It experienced higher than average volume on day. The stock decreased in value by almost -5.2% over the past week and fell -0.45% in the past month. It is currently trading -1.08% below its 50 day moving average and 1.53% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -10.65% decrease in value from its one year high of $44.52. The RSI indicator value of 38.54, lead us to believe that it is a hold for now.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants worldwide. It enables businesses of various sizes to accept payments from merchant Websites, mobile devices, and applications, as well as at offline retail locations through a range of payment solutions, including PayPal, PayPal Credit, Braintree, Venmo, and Xoom products. The company’s platform allows customers to pay and get paid, transfer and withdraw funds to their bank accounts, and hold balances in their PayPal accounts in various currencies. PayPal Holdings, Inc. was founded in 1998 and is headquartered in San Jose, California.

Agilent Technologies, Inc. (A) traded within a range of $48.01 to $49.15 after opening the day at $48.04. The company has seen its stock increase in value by 7.48% so far this year. The stock was up close to 2.73% on active volume in last trading session and closed at $48.97 per share. After the recent gain, the stock is currently holding -1.03% below its 52 week high of $49.48 and 44.97% above its 12-month low of $34.15. The shares are up by over 13.63% in the last three months, and the RSI indicator value of 61.98 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. Its Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The company’s Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment services; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. Its Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and various laboratory instrument supplies; and startup, operational, training, and compliance support, as well as asset management and consultation services. The company markets and sells its products through direct sales, electronic commerce, resellers, manufacturers’ representatives, and distributors. It has a collaboration agreement with University of Leuven to focus on detecting genetic abnormalities in cell-free DNA and embryo biopsies. Agilent Technologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.

 

Three Movers to Watch for: NextEra Energy, Inc. (NEE), Eli Lilly and Company (LLY), UnitedHealth Group Incorporated (UNH)

NextEra Energy, Inc. (NEE) grew with the stock adding 2.21% or $-0.12 to close at $22.93 on active trading volume of 3.14M compared its three months average trading volume of 2.5M. The Juno Beach Florida 33408 based company operating under the Electric Utilities industry has been trending up for the last 52 weeks, with the shares price now 15.42% up for the period and up by 1.6% so far this year. With price target of $137 and a 18.45% rebound from 52-week low, NextEra Energy, Inc. has plenty of upside potential, making it a hold with a view buy.

NextEra Energy, Inc., through its subsidiaries, generates, transmits, and distributes electric energy in the United States and Canada. The company generates electricity from gas, oil, solar, coal, petroleum coke, nuclear, and wind sources. As of December 31, 2015, it served approximately 9.5 million people through approximately 4.8 million customer accounts in the east and lower west coasts of Florida. The company had approximately 46,400 megawatts of generating capacity. It also leases fiber-optic network capacity and dark fiber to telephone, wireless, and Internet companies. The company was formerly known as FPL Group, Inc. and changed its name to NextEra Energy, Inc. in 2010. NextEra Energy, Inc. was founded in 1984 and is headquartered in Juno Beach, Florida.

Eli Lilly and Company (LLY) gained $0.8 to close the day at a new closing price of $75.38, a 1.07% increase in value from its previous closing price that moved the stock 17.45% above its 52 week low of $64.18. A total of 3.13M shares exchanged hands during the day compared with its three month average trading volume of 6.29M. The stock, which fluctuated between $74.5 and $75.4 during the day, currently situated -8.87% below its 52 week high. The stock is up by 2.13% in the past one month and down by -1.15% over the past three months. With a one year target estimate of $85.76 and RSI of 55.87, the stock still has upside potential, making it a hold for now.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

UnitedHealth Group Incorporated (UNH) shares were up in last trading by 0.15% to $162.99. It experienced lighter than average volume on day. The stock increased in value by almost 2.73% over the past week and grew 0.22% in the past month. It is currently trading 2.67% above its 50 day moving average and 14.6% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -0.62% decrease in value from its one year high of $164. The RSI indicator value of 62.85, lead us to believe that it is a hold for now.

UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, individuals, and military service members; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services. It also provides services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, Children’s Health Insurance Program, and health care programs; and health services, including commercial health and dental benefits. This segment serves through a network of 1 million physicians and other health care professionals, as well as approximately 6,000 hospitals and other facilities. Its OptumHealth segment offers health management services, including care delivery and management, wellness and consumer engagement, distribution, and health financial services. This segment serves individuals through programs offered by employers, payers, government entities, and directly with the care delivery systems. The company’s OptumInsight segment provides software and information products, advisory consulting services, and business process outsourcing and support services to hospitals, physicians, commercial health plans, government agencies, life sciences companies, and other organizations. Its OptumRx segment offers pharmacy care services and programs, including retail pharmacy network management, home delivery and specialty pharmacy, manufacturer rebate contracting and administration, benefit plan design and consultation, claims processing, and clinical program services, such as formulary management and compliance, drug utilization review, and disease and drug therapy management. The company was founded in 1974 and is based in Minnetonka, Minnesota.

 

Stocks Trend Analysis: NRG Energy, Inc. (NRG), Eli Lilly and Company (LLY), Oasis Petroleum Inc. (OAS)

NRG Energy, Inc. (NRG) continued its upward trend with the stock climbing 0.99% or $0.16 to close the day at $16.37 on light trading volume of 6.63M shares, compared to its three month average trading volume of 6.87M. The Princeton New Jersey 08540 based company has been outperforming the diversified utilities group over the past 52 weeks, with the stock gaining 86.31%, compared to the industry which has advanced 26.45% over the same period. With RSI of 86.17, the stock should still continue to rise and get closer to its one year target estimate of $0, making it a hold for now.

NRG Energy, Inc., together with its subsidiaries, operates as a power company. The company provides electricity; system power, distributed generation, solar and wind products, backup generation, storage and distributed solar, demand response, energy efficiency, electric vehicle charging stations, and on-site energy solutions; carbon management and specialty services; and various energy services, such as operations, maintenance, technical, development, and asset management services. It owns and operates approximately 50,000 megawatts of generation. The company also offers retail energy, rooftop solar, portable solar, and battery products home services; and various bundled products, which combine energy with protection products, energy efficiency, and renewable energy solutions, as well as offers installation and contract management services for residential solar customers. As of December 31, 2015, it served approximately 2.77 million recurring and 624,000 discrete customers. In addition, the company owns, operates, and develops solar and wind power projects; develops, constructs, and finances a range of solutions for utilities, schools, municipalities, and commercial markets; and trades in electric power, natural gas, and related commodity and financial products, including forwards, futures, options, and swaps. As of December 31, 2015, it operated 90 active fossil fuel and nuclear plants, 16 utility scale solar facilities, and 36 wind farms and multiple distributed solar facilities. Further, the company transacts in and trades fuel and transportation services; directly sells energy, services, and products and services to retail customers under the NRG, Reliant, and other names; and provides steam, hot water, and chilled water, as well as electricity to commercial businesses, universities, hospitals, and governmental units. NRG Energy, Inc. was founded in 1989 and is headquartered in Princeton, New Jersey.

Eli Lilly and Company (LLY) retreated with the stock falling -1.93% or $-1.47 to close at $74.85 on active trading volume of 6.59M compared its three months average trading volume of 6.3M. The Indianapolis Indiana 46285 based company operating under the Drug Manufacturers – Major industry has been trending down for the last 52 weeks, with the shares price now -5.94% down for the period and up by 1.77% so far this year. With price target of $85.05 and a 16.63% rebound from 52-week low, Eli Lilly and Company has plenty of upside potential, making it a hold with a view buy.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Oasis Petroleum Inc. (OAS) managed to rebound with the stock climbing 1.68% or $0.24 to close the day at $14.49 on higher than average trading volume of 6.57M shares, compared to its three month average trading volume of 10.85M. The Houston Texas 77002 based company has been outperforming the independent oil & gas companies by 26.8305% for last three months and its recent gains have offset losses to -4.29% YTD, versus the independent oil & gas industry which is down -0.14% for the same period. The RSI of 45.61 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Oasis Petroleum Inc., an independent exploration and production company, focuses on the acquisition and development of unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin. Its principal projects are located in West Williston and East Nesson. As of December 31, 2015, the company had 484,745 net leasehold acres in the Williston Basin; and approximately 218.2 million barrels of oil equivalent of estimated net proved reserves. Oasis Petroleum Inc. sells its oil and natural gas to refiners, marketers, and other purchasers that have access to pipeline and rail facilities. The company was founded in 2007 and is headquartered in Houston, Texas.

 

Trader Alert: Eli Lilly and Company (LLY), Colony NorthStar, Inc. (CLNS), Brookdale Senior Living Inc. (BKD)

Eli Lilly and Company (LLY) retreated with the stock falling -0.64% or $-0.49 to close at $76.32 on light trading volume of 5.05M compared its three months average trading volume of 6.27M. The Indianapolis Indiana 46285 based company operating under the Drug Manufacturers – Major industry has been trending down for the last 52 weeks, with the shares price now -4.99% down for the period and up by 3.77% so far this year. With price target of $85.05 and a 18.92% rebound from 52-week low, Eli Lilly and Company has plenty of upside potential, making it a hold with a view buy.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Colony NorthStar, Inc. (CLNS) gained $0.3 to close the day at a new closing price of $14.12, a 2.17% increase in value from its previous closing price that moved the stock 71.68% above its 52 week low of $9.17. A total of 5.05M shares exchanged hands during the day compared with its three month average trading volume of 3.94M. The stock, which fluctuated between $13.69 and $14.15 during the day, currently situated -5.68% below its 52 week high. The stock is up by 2.67% in the past one month and up by 11.35% over the past three months. With a one year target estimate of $15.25 and RSI of 50.86, the stock still has upside potential, making it a hold for now.

The firm invests in the real estate markets of North America and Europe. Its investment portfolio is primarily composed of real estate equity; real estate and real estate-related debt; and investment management of company-sponsored private equity funds and vehicles. The firm invests in wide spectrum of commercial real estate property types, including but not limited to, office, industrial, retail, hospitality, education, single-family and multifamily residential assets, and geographies, primarily within North America and Europe. It was formerly known as Colony Financial, Inc. Colony Capital, Inc. was formed on June 23, 2009 and is based in Los Angeles, California.

Brookdale Senior Living Inc. (BKD) shares were down in last trading by -1.66% to $15.41. It experienced higher than average volume on day. The stock decreased in value by almost -2.53% over the past week and grew 17.63% in the past month. It is currently trading 19.4% above its 50 day moving average and -3.45% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -20.65% decrease in value from its one year high of $19.42. The RSI indicator value of 64.31, lead us to believe that it is a hold for now.

Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates through five segments: Retirement Centers, Assisted Living, Continuing Care Retirement Centers (CCRCs) – Rental, Brookdale Ancillary Services, and Management Services. The Retirement Centers segment owns or leases communities comprising independent living and assisted living units in a single community that are primarily designed for middle to upper income senior citizens. The Assisted Living segment owns or leases communities consisting of freestanding, multi-story communities, and freestanding single story communities, which offer housing and 24-hour assistance with activities of daily life to mid-acuity frail and elderly residents. This segment also operates memory care communities for residents with Alzheimer’s disease and other dementias. The CCRCs – Rental segment owns or leases communities that offer various living arrangements and services to accommodate various levels of physical ability and health. The Brookdale Ancillary Services segment provides outpatient therapy, home health, and hospice services to residents of its communities, as well as to other senior living communities. The Management Services segment operates communities under the management agreements. As of December 31, 2015, the company operated 130 retirement center communities with 24,486 units; 915 assisted living communities with 62,567 units; and 78 CCRCs with 21,367 units, as well as owned or leased 959 communities with 81,067 units and provided management services with respect to 164 communities with 27,353 units for third parties or unconsolidated ventures. Brookdale Senior Living Inc. is headquartered in Brentwood, Tennessee.